Miripla CAS 141977-79-9 Miriplatin SMP-11355 SM -11355 DACHPM M 11355

Model: C34H68N2O4Pt
Place of Origin: Zhejiang,China (Mainland)
Brand: MOSINTER
Name: Miripla
CAS: 141977-79-9
Molecular Formula: C34H68N2O4Pt
Content: >98%
Specification: enterprise standard
Molecular Weight: 764.02206
Alias: M 11355

inquiry

skype basketAdd to Basket  Edit

Share |

Product Description

Payment & Shipping Terms Supply Capacity
Payment Terms:L/C, T/T, WUProduction Capacity:100 kg/Year
Min. Order:50 GramPacking:According to customer...
Means of Transport:Ocean, Air, LandDelivery Date:Within 7 days

Miripla  (CAS: 141977-79-9)

Appliacation: The new liver cancer medicine

Appearance: white powder

Platinum (Miriplatin Hydrate) was developed by Japan's sumitomo pharmaceutical co., fat-soluble anticancer medicine, platinum complex on October 16, 2009, approved by Japan's health ministry, used in the treatment of hepatocellular carcinoma (HCC). On January 20, 2010, Miriplatin Hydrate and its special mixed suspension on sale at the same time.

Efficacy and pharmacological

Use in the liver transplantation rat liver cancer cell lines AH109A or human liver cell line of Li - seven mice transplanted liver cancer model, evaluation m platinum mixed suspension inhibition of cancer cell proliferation in the body. Platinum mixed suspension, according to the results of meters to inhibit cancer cell proliferation, dose related way and when mixed suspension of meters platinum is 20 mg/mL of tumor cell proliferation rate significantly reduced. M platinum suspension liquid is administered a single dose, for the same model of liver cancer has antitumor dose related.

Category: Antineoplastic Drugs API

Related Category: Other Pharmaceutical API  Veterinary Medicine API  Diagnostic Agents API  Vitamin Preparation API  Psychotropic Drugs API 


«
Offline Showroom in USA
QR Code